Ergomed plc CEL-SCI Corporation issues restricted shares (5035O)

TIDMERGO

RNS Number : 5035O

Ergomed plc

21 August 2017

PRESS RELEASE

FOR IMMEDIATE RELEASE

CEL-SCI Corporation issues restricted shares to Ergomed for partial settlement of receivable

London, UK - 21 August 2017: Ergomed plc (LSE: ERGO) ('Ergomed' or the 'Company'), a company dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, today announces that it has entered into an agreement with its co-development partner, CEL-SCI Corporation (NYSE: CVM) ('CEL-SCI'), whereby CEL-SCI will issue 480,000 shares of restricted stock which, upon registration, may be sold subject to a volume restriction of no more than five per cent of the trading volume in any single day.

ENDS

Enquiries:

 
 Ergomed plc                                           Tel: +44 (0) 
                                                        1483 503205 
 Dan Weng (Chief Executive Officer) 
 Stephen Stamp (Chief Financial 
  Officer) 
 
 Numis Securities Limited                              Tel: +44 (0) 
                                                       20 7260 1000 
 Michael Meade / Freddie Barnfield 
  (Nominated Adviser) 
 James Black (Joint Broker) 
 
 N+1 Singer                                            Tel: +44 (0) 
                                                       20 7496 3000 
 Alex Price (Joint Broker) 
 
 Consilium Strategic Communications                    Tel: +44 (0) 
  - for UK enquiries                                   20 3709 5700 
 Chris Gardner / Mary-Jane              [e-mail] 
  Elliott 
  Ivar Milligan / Philippa Gardner 
 
 MC Services - for Continental                         Tel: +49 211 
  European enquiries                                      5292 5222 
 Anne Hennecke 
 
 

About Ergomed

Ergomed provides specialist services to the pharmaceutical industry and develops drugs both wholly-owned and through partnerships. Ergomed's fast-growing, profitable service offering spans all phases of clinical development and post-approval pharmacovigilance and medical information. Drawing on more than 20 years of expertise in drug development, Ergomed is also building a growing portfolio of drug development partnerships and programmes, including wholly-owned proprietary products for the treatment of surgical bleeding. For further information, visit: http://ergomedplc.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCQFLBLDVFBBBZ

(END) Dow Jones Newswires

August 21, 2017 02:06 ET (06:06 GMT)